Dividend Informer Q4 2024 Update: AbbVie

AbbVie shrugs off the Humira decline, fueled by immunology and oncology growth; 2025 EPS looks bright.

Here is the Dividend Informer team’s update on a covered stock. See below for updated buy/sell prices, a report on recent conditions and expectations for the future, and current analysis metrics.

AbbV…